Psychedelics and Wellness Study (PAWS)

Depression, Anxiety, PTSD Clinical Trial

— PAWS  

Official title:

Psychedelics and Wellness Study (PAWS): An Online Anonymous Survey Investigating the Interrelationship Between Past Psychedelic Use and Its Impact on Levels of Wellness

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04040582
• Other study ID #: WILD 5 Wellness
• Status: Completed
• Start date: September 30, 2019
• Est. completion date: July 25, 2023

Study information

• Verified date: December 2023
• Source: WILD 5 Wellness
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The Psychedelics and Wellness Study (PAWS), is an anonymous online survey investigating the interrelationship between psychedelics and wellness. The study population is adults ages 18 and older that have taken a psychedelic at least once. The maximum sample size is 5,000 survey respondents. It is expected that this anonymous online survey will support the hypothesis that there is a robust interrelationship between past psychedelic use and its impact on wellness.

Description:

Following a four-decade moratorium, the therapeutic use of psychedelics has once more captured the collective attention of the medical community and the public at large. Now, at the forefront of a renaissance in psychedelic research, this study is investigating the interrelationship of psychedelics and mental wellness - a state of well-being in which the individual realizes his or her own abilities, can cope with the normal stresses of life, can work productively and fruitfully, and is able to make a contribution to his or her community. This work will be unique in that it will collect both objective and subjective data to assess the interrelationship between psychedelic and wellness. It will lend support to the growing body of research in the use of psychedelics for both mental health conditions and the pursuit of overall mental wellness.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3234
• Est. completion date: July 25, 2023
• Est. primary completion date: July 25, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Adults ages 18 and older that have taken a psychedelic at least once.

Exclusion Criteria:

• Individuals less than 18 years old and have previously never taken a psychedelic substance.

Related Conditions & MeSH terms

• Depression
• Depression, Anxiety, PTSD

Locations

Country	Name	City	State
United States	WILD 5 Wellness	Austin	Texas

Sponsors (1)

Lead Sponsor	Collaborator
WILD 5 Wellness

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Patient Health Questionnaire-9 (PHQ-9)	The PHQ-9 is a nine-item depression self-report questionnaire for screening and measurement of severity of major depression. Scores range from 0-27 (Lower scores = Less depression).	Through study completion, an average of 1 year
Primary	Change in Generalized Anxiety Disorder-7 (GAD-7)	The GAD-7 is a seven-item self-report questionnaire for screening and measurement of severity of generalized anxiety disorder. Scores range from 0-21 (Lower scores = Less anxiety).	Through study completion, an average of 1 year
Primary	Change in HERO Wellness Scale	The HERO Wellness Scale is a brief 5-item scale designed to measure four wellness traits plus perceived mental wellness. Scores range from 0-50 (Lower scores = Lower levels of mental wellness).	Through study completion, an average of 1 year